Brand Name: MIXOPENEM®
Generic name: Imipenem / Cilastatin
MIXOPENEM® is a category of antibiotics and subset of the Carbapenems group.
MIXOPENEM® used in the cure of aerobic and anaerobic infections caused by gram positive and negative bacterias that are sensitive to it including infections of the abdomen, bones and joints, soft tissue and skin, urinary and biliary ducts, pneumonia in effect of hospitalization and septicemia in patients with immune system weakness.
Mechanism of action:
This drug is beta-lactam carbapenem, which is different from penicillins in the presence of saturated carbon instead of sulfur in the Pentagon ring of the molecule.
The mechanism of The effect of this drug is similar to penicillins and its range of effects is wide. MIXOPENEM® prevents bacterial cell wall synthesis. The antimicrobial activity spectrum of this drug includes most of the gram positive, gram negative and anaerobic bacterias including Staphylococcus, Streptococcus, Escherichia coli, Klebsiella, Proteus, Enterobacter, Pseudomonas aeruginosa and Bacterioides Species, Clostridium difficile and other species of Pseudomonas.
Cilastatin inhibits the activity of the enzyme dipeptidase (which disables MIXOPENEM®).
Disposing of this drug is mainly renal. A portion of the drug in the kidneys Turns into Inactive metabolites and Nephrotoxic by Dehydroepidase I enzyme. therefore, this drug is always used with Cilastatin that hydrolyptidase I inhibitor, which increases the concentration of drug in the kidney and urine but does not affect the plasma concentration of the drug. The half-life of both compounds is about one hour. The bioavailability of the drug after the injection of muscle is about 75%.
If you have a history of excessive sensitivity to other beta-lactam antibiotics, it should not be used.
MIXOPENEM® should be used with caution in patients with renal impairment.
Since MIXOPENEM® is always consumed with Cilastatin, the side effects reported are related to the combination of two compounds. Complications reported for MIXOPENEM® are similar to the side effects of other beta-lactam antibiotics, which include reactions of extreme susceptibility, gastrointestinal complications, infections caused by resistant organisms (including pseudomembranous colitis), neurological complications and skin complications.
There is a risk of seizure when taking gonciquinavir with a combination of imipenem-silasartin.
Changing the color of urine to red is reported, especially in children after taking MIXOPENEM®.
Redness, pain and thrombophlebitis may occur at the injection site
adults: Via intramuscular injection of 700-500 mg every 12 hours, from intravenous infusion of 1-1 g/ day in 3 to 4 divided doses, this amount for infections caused by less sensitive bacteria, 50 to 50 mg / kg / day The maximum dose of 4 g / day in 3-4 doses increases and to prevent post-operative infections, first start at 1 gram at the start of the procedure, which is repeated 3 hours later and In high-risk surgeries (such as colorectal surgery), 500 mg is given as an intravenous infusion 8 and 16 hours after the start of the surgery.
Childs: In children aged 3 months or more, intravenous infusion is used at 60 mg / kg / day (up to a maximum of g / day 2) in four divided doses. Dosage in children weighing more than 40 kg is similar to adults.
Powder For Injection MIXOPENEM® 250/250mg: Imipenem (as Monohydrate) 250mg + Cilastatin (as Sodium) 250mg
Powder For Injection MIXOPENEM® 500/500mg: Imipenem (as Monohydrate) 500mg + Cilastatin (as Sodium) 500mg
MIXOPENEM® is available in two doses of 250 and 500 mg in the pharmacy basket of pars pharmed company.
The primary substance of this drug Is provided From the Company in italy that is one of the best producers of this basic material.
Providing all documents related to the manufacture and analysis of this product to the Food and Drug Agency, the license and the export license was issued. This product is purely for the hospital and is not distributed in public pharmacies.